Ocular Therapeutix
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bio...
Latest News
8 days ago · seekingalpha.com
Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call TranscriptOcular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript
8 days ago · marketbeat.com
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings CallOcular Therapeutix NASDAQ: OCUL plans to submit a U.S. application in the fourth quarter of 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, executives said on the company's third-quarter earnings call.
8 days ago · zacks.com
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue EstimatesOcular Therapeutix (OCUL) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to a loss of $0.37 per share a year ago.
15 days ago · globenewswire.com
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, November 9, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2026.
19 days ago · globenewswire.com
Ocular Therapeutix™ to Participate in November Investor and Scientific ConferencesBEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.
23 days ago · seekingalpha.com
Ocular Therapeutix: The Drug Won, The Stock Lost, And That's The OpportunityOcular Therapeutix is rated Buy (speculative) with a 12-month price target of $7.90, reflecting a lopsided risk/reward profile. AXPAXLI's strong Phase 3 SOL-1 results support a clear regulatory path, with NDA filing expected in Q4 and potential 2027 launch. The market is pricing in $1.26 billion in peak U.S. sales for OCUL after competitor advances, lost takeover premium, and rising cash burn.
24 days ago · seekingalpha.com
Ocular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing TranscriptOcular Therapeutix, Inc. (OCUL) Discusses Progress and Regulatory Update on AXPAXLI NDA Filing Transcript
2 months ago · globenewswire.com
Ocular Therapeutix™ to Participate in October Scientific and Investor ConferencesBEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.
3 months ago · globenewswire.com
Ocular Therapeutix™ to Participate in September and October Investor and Scientific ConferencesBEDFORD, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in September and October 2026.
3 months ago · seekingalpha.com
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI TranscriptOcular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove OCUL